Best Life Sciences Companies in Connecticut, United States
The 258 best Life Sciences companies in Connecticut, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Treeline Biosciences.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Connecticut
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Treeline Biosciences Developer of transformative precision medicines to treat cancer 64Funding top 18%Patents top 21%Innovation top 24%Moat top 26% All 9 signals ▾Fundingtop 18% Patentstop 21% Innovationtop 24% Moattop 26% Talenttop 38% Techtop 48% Marketbottom 45% Globalbottom 40% Newsbottom 31% Funding: Raised $895M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Patents: 103 patents matched (strict assignee match) · 103 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $895M | 9 mo ago | 148 | Joshua Bilenker Co-Founder & CEO | SanityApple iCloud MailNode.js+16 | 103 patents Patents concentrated in chemistry & materials | — |
| 2 | Butterfly Network Portable ultrasound system for external ultrasound imaging | $350M | 51 mo ago | 225 225 → 449 (+100%) | Jonathan Rothberg Co-Founder & CEO | WebflowCart FunctionalityApple iCloud Mail+27 | 1,000 patents Handheld portable ultrasound imaging with microfabricated transducers and automated data handling | 1 launch |
| 3 | Biohaven Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases 72Funding top 19%News top 27%Growth top 30%Market top 40% All 8 signals ▾Fundingtop 19% Newstop 27% Growthtop 30% Markettop 40% Techtop 40% Fin. healthtop 43% Moatbottom 41% Globalbottom 32% Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 13 BI events in 12 mo (of 43 tracked, 9 types) · +86% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $250M | 13 mo ago | 202 | — | DrupalApple iCloud MailMicrosoft 365+30 | — | 1 internship · 1 expansion |
| 4 | Sema4 Provider of genome-based diagnostic testing solutions for reproductive health and oncology | $241M | 49 mo ago | 1,200 | — | — | — | — |
| 5 | Halda Therapeutics Developer of precision therapeutics for cancer treatment | $217M | 22 mo ago | 30 | Craig Crews Founder & CEO | WordPressMySQLPHP+15 | — | — |
| 6 | melinta therapeutics Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to… | $186M | 87 mo ago | 162 | — | — | 376 patents Novel boronic acid‑based beta‑lactamase inhibitors for treating resistant bacterial infections | — |
| 7 | IsoPlexis Developer of multiplexed single-cell analysis tools for the diagnostics and life science research | $186M | 65 mo ago | 195 | — | — | 72 patents High-throughput single-cell capture, secretion profiling, and miniaturized sequencing technologies. | — |
| 8 | Rallybio Developer of antibodies & protein therapies for rare disorders | $182M | 26 mo ago | 43 43 → 23 (-47%) | Stephen Uden Co-Founder | WordPressMySQLPHP+14 | — | — |
| 9 | NextCure Developer of next-generation immuno-oncology-based drugs 69News top 21%Funding top 23%Patents top 25%Moat top 26% All 11 signals ▾Newstop 21% Fundingtop 23% Patentstop 25% Moattop 26% Growthtop 30% Innovationtop 32% Fin. healthtop 43% Markettop 44% Partnerstop 45% Techbottom 46% Globalbottom 42% News: 7 BI events in 12 mo (of 19 tracked, 5 types) · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo Funding: Raised $175M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $175M | 7 mo ago | 87 | — | WordPressDrupalMySQL+24 | 77 patents Therapeutic antibodies and ADCs targeting novel immune checkpoints for cancer treatment | — |
| 10 | Kolltan Pharmaceuticals Using antibody to target different tyrosine kinase receptors to treat cancer. | $141M | 147 mo ago | 41 | — | — | — | — |
| 11 | Spine Wave Manufacturer of expandable and less invasive surgical spinal medical devices | $136M | 95 mo ago | 80 80 → 96 (+20%) | Mark LoGuidice Co-Founder | RequireJSApache HTTP ServerjQuery+1 | 548 patents Spinal interbody fusion implants and modular tensioned fixation screws for vertebral stabilization | — |
| 12 | Cybrexa Therapeutics Developer of therapeutics that target the tumour microenvironment | $118M | 47 mo ago | 19 | — | WordPressMySQLPHP+21 | — | — |
| 13 | Arvinas Developer of small molecule drugs to target and degrade disease causing proteins | $100M | 83 mo ago | 266 266 → 305 (+15%) | — | DrupalApple iCloud MailMicrosoft 365+30 | — | 1 partnership |
| 14 | OrphAI Therapeutics Developer of treatments for rare orphan conditions | $98M | 110 mo ago | 16 | Brigette Roberts CEO | WebflowjQueryHSTS+5 | — | — |
| 15 | Identifeye Health Developer of a non-invasive test to detect health conditions through the eyes | $80M | 61 mo ago | 48 | Jonathan Rothberg Co-Founder | WebflowApple iCloud MailGoogle Workspace+14 | — | — |
| 16 | Transgenomic Molecular Diagnostics in cardiology, oncology, and inherited diseases | $72M | 109 mo ago | 53 | — | — | — | — |
| 17 | Simcha Therapeutics Developer of therapeutics with anti-tumor effect | $65M | 12 mo ago | 15 | Aaron Ring Founder | WordPress Block EditorWordPressMySQL+17 | — | — |
| 18 | NanoViricides Targeted antiviral therapeutics 14Funding top 26%Moat top 48%Growth bottom 40%News bottom 35% All 7 signals ▾Fundingtop 26% Moattop 48% Growthbottom 40% Newsbottom 35% Globalbottom 30% Marketbottom 29% Techbottom 24% Funding: Raised $47.0M across 7 rounds · 7 rounds over 15 yrs (0.5/yr) Moat: Editorial + unicorn rating 5/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 14/100 | $47M | 7 mo ago | 17 | — | RequireJSHSTSOpen Graph | — | — |
| 19 | Azitra Developer of micriobiome based therapeutics solution for treating skin atopic dermatitis or eczema | $37M | 65 mo ago | 17 17 → 13 (-24%) | Francisco Salva CEO | DrupalPHPBootstrap+20 | — | 1 launch |
| 20 | Ikonisys Developer of non-invasive diagnostic tests for cancer detection | $35M | 15 mo ago | 8 | Michael Kilpatrick Founder | — | 235 patents Automated fluorescence microscopy and digital pathology for cancer detection | — |
| 21 | Biorez Synthetic products for soft tissue regeneration of anterior cruciate ligament injuries | $29M | 59 mo ago | 24 | — | — | — | — |
| 22 | Tangen Biosciences Developer of a molecular diagnostics platform | $24M | 36 mo ago | 10 | John Davidson Co-Founder | — | — | — |
| 23 | Bexorg Developer of whole-brain perfusion model for drug discovery | $23M | 8 mo ago | — | Zvonimir Vrselja CEO | Apple iCloud MailGoogle WorkspaceNode.js+14 | 8 patents Advanced organ perfusion systems and ML-driven brain perfusion simulation technologies | 1 partnership |
| 24 | UCAN Manufacturer of dietary supplements | $16M | 36 mo ago | 30 | — | Cart FunctionalityShopifySentry+51 | 2 patents Heat‑moisture‑treated carbohydrate ingredients for pharmaceutical and nutraceutical applications | — |
| 25 | MindImmune Therapeutics Developing immunotherapeutics to restore neural connections in neurodegenerative diseases 14Talent top 28%Funding top 33%Moat top 48%Global bottom 32% All 6 signals ▾Talenttop 28% Fundingtop 33% Moattop 48% Globalbottom 32% Techbottom 23% Marketbottom 19% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $13.7M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 14/100 | $14M | 3 mo ago | 7 | Bob Nelson Co-Founder & Vice President of Biology | — | — | 1 expansion |
| 26 | Cellinfinity Bio Developer of cell therapies for cancer treatment | $13M | 17 mo ago | 9 | Sidi Chen Founder | — | — | — |
| 27 | Jumo Health Provider of healthcare education and clinical trial solutions for patients and professionals | $13M | 21 mo ago | 86 | Brittany Erana CEO | WordPressMySQLPHP+16 | — | — |
| 28 | Modifi Bio Developer of therapeutics for the treatment of cancer | $12M | 21 mo ago | 11 | Ranjit Bindra Co-Founder | — | — | — |
| 29 | Weave AI-powered platform to accelerate investigational new drug submission | $10M | 8 mo ago | 9 | Umut Eser Co-Founder & Chief AI Officer | — | — | — |
| 30 | Cytogel Pharma Provider of an analgesic product candidate and polymer and hydrogel drug delivery platform technologies | $9M | 8 mo ago | 7 | C. Maglaris CEO | — | — | — |
| 31 | Wavelet Developer of fetal brain monitoring technology using electroencephalography and algorithms | $7M | 2 mo ago | — | Liz Golden Co-Founder & CEO | — | — | — |
| 32 | ProteoWise Provider of a platform for the analysis of proteomics | $6M | 18 mo ago | — | Mikhail Kostylev Co-Founder | — | 6 patents Multiplexed biomarker capture and analysis platforms for biological samples | — |
| 33 | TECLens Developer of a noninvasive vision correction treatment | $6M | 16 mo ago | — | David Acker Executive Chairman and Co-founder | WordPressMySQLPHP+17 | 48 patents Patents concentrated in health & consumer products | 1 job opening · 1 launch |
| 34 | Mitotherapeutix Developer of small molecules based drug using siRNA technology for various diseases | $5M | 15 mo ago | 5 | Robert Hemley Co-Founder & COO | — | 8 patents Targeted multivalent ligand drug delivery and epigenetic J‑protein expression inhibition | — |
| 35 | Inventure Provider of healthcare services | $4M | 4 mo ago | — | Richard Deslauriers Founder & Chairman | — | 44 patents Stable lanthanide-based macrocyclic MRI contrast agents and their synthesis methods | — |
| 36 | RNAConnect Provider of reverse transcriptase solutions for RNA analysis | $4M | 14 mo ago | — | Ryan Muldoon Co-Founder & CEO | Cart FunctionalityShopifyShop Pay+17 | — | 1 launch · 1 partnership |
| 37 | Flyp Nebulizer Developer of a portable nebulizer for asthma and COPD | $4M | 4 mo ago | 24 | — | Cart FunctionalityRubyRuby on Rails+15 | — | — |
| 38 | Potentiometric Probes Developer of voltage-sensitive dyes for biological research | $3M | 14 mo ago | — | Ping Yan Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | — |
| 39 | inveniai Developer of an artificial intelligence platform for drug discovery and development | $3M | 23 mo ago | 45 | — | — | 2 patents Therapeutic anti-inflammatory drug compositions for gastrointestinal disease treatment | — |
| 40 | Intus Bio Developer of sequencing technology for microbiome testing, pathogen identification, and tracking | $3M | 13 mo ago | 9 | Ken Beers CEO | — | — | — |
| 41 | Sed Med Provider of medical equipment support services | $3M | 5 mo ago | 5 | Jeremy Bronen CEO | — | — | — |
| 42 | Enrich Biosystems Provider of cell therapy development platform services | $2M | 7 mo ago | 17 | Dong Wang Co-founder | WordPressMySQLPHP+21 | — | — |
| 43 | CaroGen Corporation Immunotherapy company developing novel RNA-based artificial virus platform for infectious diseases | $2M | 30 mo ago | 8 | Valerian Nakaar Co-Founder | — | — | — |
| 44 | Verinomics Developer of genomic and gene editing platforms for crop improvement | $2M | 15 mo ago | 13 | Stephen Dellaporta Founder | — | — | — |
| 45 | AtlasXomics Provider of omics data analysis platform | $2M | 11 mo ago | 22 22 → 22 (+0%) | — | Cart FunctionalitySquarespace CommerceSquarespace+17 | 13 patents Microfluidic chiplet platforms enabling high‑throughput spatial omics assays | — |
| 46 | Invea Therapeutics Developer of therapeutics for inflammatory gastrointestinal and hepatobiliary disorders | $2M | 7 mo ago | 12 | Krishnan Nandabalan Founder | — | — | — |
| 47 | Gynion Developer of therapeutic devices for women health applications | $969K | 13 mo ago | 2 | Steven Goldstein Co-Founder & Chief Medical Officer | — | 14 patents Intrauterine drug delivery systems for localized therapeutic agent administration. | — |
| 48 | LambdaVision Provider of a protein-based retinal prosthesis for retinal degenerative diseases | $650K | 7 mo ago | 7 | — | WordPressMySQLPHP+20 | 6 patents Retinal cell stimulation therapies for vision restoration | 1 partnership |
| 49 | Kelyniam Custom prosthetics using CAD technology | $250K | 18 mo ago | 4 | — | — | — | — |
| 50 | QCDx Developer of instruments for the detection of rare cells in the blood circulation | $130K | 13 mo ago | 9 | — | — | — | — |
Top 12 Life Sciences companies in Connecticut
#1
Series A · Stamford, Connecticut · founded 2021 · 148 employees$895.4Mraised▾
Developer of transformative precision medicines to treat cancer. The company's drug discovery platform includes mechanistic biology, medicinal chemistry, computational science, structural biology & protein science.
- Aug 2025Series A$200.1M
- Oct 2024Series A$421.8M
- Sep 2022Series A$262M
- Apr 2021Series A$211.7M
#2
Public · New Haven, Connecticut · founded 2015 · 87 employees$175.4Mraised▾
Developer of next-generation immuno-oncology-based drugs. The proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. The pipeline candidates include NC318 for tumor and macrophages, NC410 for myeloid and T-cells, NC762 for tumors, NC252 for leukemia cells, and others.
- Nov 2025Post IPO$21.5M
- Nov 2018Series B$93.4M
- Nov 2018Series A$15M
- Jan 2016Series A$67M
#3
Public · West Haven, Connecticut · founded 2005 · 17 employees$47Mraised▾
NanoViricides discovers, develops and commercializes therapeutics to treat viral infections. Nanoviricide is an antiviral agent based on the TheraCour polymeric micelle technology. This is a biomimetic platform technology has enabled the Company to rapidly develop highly effective drug candidates against a number of viral diseases. Currently developing drugs against five diseases: FluCide, a single drug against all influenzas including pandemic viruses, bird flu (H5N1), and highly pathogenic strains; HIVCide, which was found to be so effective in SCID-hu mouse model studies that it is widely believed that it could result in a “functional cure” of HIV/AIDS; HerpeCide for oral and genital herpes; DengueCide, a single drug to combat all dengue virus types; and a broad-spectrum antiviral for infections of the external eye.
- Nov 2025Post IPO$6M
- Feb 2019Post IPO$2.5M
- Jan 2014Post IPO$20M
- Feb 2013Post IPO$6M
#4
Series A · Ledyard, Connecticut · founded 2016 · 7 employees$13.7Mraised▾
Developing immunotherapeutics to restore neural connections in neurodegenerative diseases. The company is focused on creating novel therapies that target the immune system to treat neurodegenerative conditions like Alzheimer's disease. Their approach involves blocking harmful immune cells from entering the brain to prevent neuroinflammation and preserve brain health. They are advancing a first-in-class monoclonal antibody, designed to stop inflammatory damage. The company's scientific team brings extensive experience in CNS drug discovery to develop breakthrough therapeutics for brain disease. They are affiliated with the George & Anne Ryan Institute for Neuroscience and collaborate with experts in neuroscience and immunology. Their goal is to enable people to live with dignity by stopping neuroinflammatory disease progression and preserving neuronal connections. This is a biotech company focused on research and development of pharmaceutical products.
- Mar 2026Series A$5M
- Nov 2025Series A$15.2M
- Jun 2022Series A$12.4M
- Nov 2019Seed$750K
#5
Seed · New Haven, Connecticut$7Mraised▾
Developer of fetal brain monitoring technology using electroencephalography and algorithms. This system utilizes sensors to record brain activity during pregnancy. Machine learning processes the collected data to provide analysis regarding fetal neurological development. The technology functions as a non-invasive tool for healthcare providers to observe brain function and identify potential health issues.
- Apr 2026Seed$7M
#6
Public · New Haven, Connecticut · founded 2022 · 202 employees$250Mraised▾
Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases. The company leverages its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder, and spinocerebellar ataxia and myostatin inhibition for neuromuscular diseases.
- Apr 2025Post IPO$250M
#7
Series B · New Haven, Connecticut · founded 2018 · 15 employees$65Mraised▾
Developer of therapeutics with anti-tumor effect. The lead candidate of the company is ST-067, based on the immune system and IL-18 cytokine which is having potent antitumor effects. The company claims to have shown a positive response on the animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors.
- Jun 2025Series B$7.1M
- Jan 2022Series B$40M
- Jun 2020Series A$25M
- Jul 2018Series A$4.4M
#8
Deadpooled · Southbury, Connecticut · founded 2014$4.2Mraised▾
Developer of medical equipment designed to aid the medical imaging field. The company's devices are reliable and of low cost and have lower free Gd(III) Gadolinium-based contrast agent (GBCA) designed for MRI Contrast Agent, enabling healthcare providers to get good MRI contrasts and improve the lives of patients.
- Feb 2026Seed$200K
- Jul 2025Seed$361.5K
- Mar 2023Seed$2.1M
- Jan 2021Seed$45K
#9
Series A · New Haven, Connecticut · founded 2021$23Mraised▾
Developer of whole-brain perfusion model for drug discovery. The company's proprietary technology transforms brains into discovery machines by perfusing whole human and porcine brains, generating highly dimensional datasets consisting of cellular responses.
- Oct 2025Series A$23M
#10
Series B · Fairfield, Connecticut · founded 2017 · 24 employees$4Mraised▾
Flyp Nebulizer is a developer of portable nebulizer for the treatment of asthma and COPD. The Flyp nebulizer is a small HypersoniQ powered (internal disk vibrates at high speed) pocket-sized portable nebulizer and USB-rechargeable. The nebulizer is used to deliver or dispense medication for treating asthma or COPD.
- Feb 2026Series B$613.3K
- Sep 2019Series B$4M
#11
Series B · Fairfield, Connecticut · founded 2002 · 7 employees$8.6Mraised▾
Provider of an analgesic product candidate, and polymer and hydrogel drug delivery platform technologies. The company's lead candidate Cyt-1010 is an analgesic for moderate to severe pain. Also, provides drug delivery technologies such as polymers and hydrogels to enhance the kinetic profiles of human drugs, as well as pharmacologic properties of veterinary medicines.
- Oct 2025Series B$250K
- Jun 2023Series B$1.8M
- May 2021Series A$956.9K
- Mar 2019Conventional Debt$100K
#12
Series A · New Haven, Connecticut · founded 2022 · 9 employees$10Mraised▾
AI-powered platform to accelerate investigational new drug submission. The platform accelerate document drafting, navigate complex source documents, streamline reviews, and automatic content updates. It has applications for pharmaceutical companies, biotech, and regulatory consultants.
- Oct 2025Series A$20M
- May 2024Seed$10M
- Aug 2022Seed$1.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.